Nxera Pharma's Daridorexant Hits Key Endpoints in South Korea Phase 3 Trial

Event summary

  • Nxera Pharma's Phase 3 trial of daridorexant 50 mg in South Korea met all primary and secondary endpoints, including subjective total sleep time (sTST), latency to sleep onset (sLSO), and wake after sleep onset (sWASO).
  • The company plans to submit a marketing authorization application in South Korea in Q1 2026, with approval expected in Q1 2027.
  • Daridorexant is already approved and marketed in Japan as QUVIVIQ® under a partnership with Shionogi.
  • Insomnia affects 15-25% of South Korea's adult population, or 6.5-11 million people.

The big picture

Nxera Pharma's positive Phase 3 results for daridorexant in South Korea position it to tap into a large, underserved insomnia market in Asia. The company's strategic partnerships with Shionogi in Japan and Idorsia in the West highlight its global ambitions. Success in South Korea could serve as a blueprint for further expansion in high-prevalence insomnia markets.

What we're watching

Regulatory Timeline
Whether Nxera can maintain its aggressive timeline for South Korean approval amid potential regulatory scrutiny.
Market Expansion
How quickly Nxera can leverage this success to expand daridorexant's reach beyond Japan and South Korea.
Competitive Dynamics
The pace at which competitors like Idorsia and Simcere may respond in the Asian market.